Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease (MermaiHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00665223
Recruitment Status : Completed
First Posted : April 23, 2008
Last Update Posted : July 21, 2016
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.

Condition or disease Intervention/treatment Phase
Huntington's Disease Drug: ACR16 Drug: Placebo Phase 3

Detailed Description:
The primary objective in the present study is to confirm whether ACR16 is efficacious in improving voluntary motor function in Huntington's disease, symptoms that seem to be most important for the functional disability associated with the disorder. To achieve this, patients are randomised to ACR16 45mg qd, ACR16 45mg bd, or placebo treatment in equal proportions in a parallel design for treatment duration of 26 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 437 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease
Study Start Date : April 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ACR16 - once daily dose
Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, ACR16 45 mg capsule and one placebo capsule were taken as two separate doses.
Drug: ACR16
45 mg capsules Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
Other Name: Pridopidine

Drug: Placebo
Placebo capsules. Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.

Experimental: ACR16 - twice daily dose
Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, an ACR16 45 mg capsule was taken twice daily as two separate doses (total dose: 90 mg).
Drug: ACR16
45 mg capsules Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
Other Name: Pridopidine

Placebo Comparator: Placebo
Participant received a placebo capsule once daily for four weeks. Weeks 5-26, a placebo capsule was taken twice daily as two separate doses.
Drug: Placebo
Placebo capsules. Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.




Primary Outcome Measures :
  1. The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment. [ Time Frame: last timepoint at which outcome is assessed is after 26 weeks ]

Secondary Outcome Measures :
  1. Safety and tolerability assessed from adverse event profile. [ Time Frame: After 1, 4, 5, 8, 12, 26 and 30 weeks ]
  2. The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety. [ Time Frame: At 4, 8, 12 and 26 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to provide written Informed Consent prior to any study related procedure.
  • Huntington's disease diagnosed with the aid of clinical features and a positive family history and/or the presence of ≥ 36 CAG repeats in the Huntington gene.
  • Male or female age ≥ 30 years.
  • Willing and able to take oral medication and able to comply with the study specific procedures.
  • Ambulatory, being able to travel to the assessment centre, and judged by the Investigator as likely to be able to continue to travel for the duration of the study.
  • Availability of a caregiver or family member to accompany the patient.
  • A sum of ≥ 10 points on the mMS at the screening visit.
  • For patients taking allowed antipsychotic medication, the dosing of medication must have been kept constant for at least 6 weeks before randomisation. The allowed antipsychotic medication is Amisulpride, Haloperidol, Olanzapine, Risperidone, Sulpiride, or Tiapride.
  • For patients taking allowed antidepressant or other psychotropic medication, the dosing of medication must have been kept constant for at least 6 weeks before randomisation.
  • Willing to provide a blood sample for CAG analysis (where CAG result is not already available).
  • In France only, the patient must be affiliated to a social security system or be a beneficiary of such a system.

Exclusion Criteria:

  • Unable to give written informed consent.
  • Treatment with any non-allowed antipsychotic medication within 12 weeks of randomisation. The non-allowed antipsychotic medication is any medication other than Amisulpride, Haloperidol, Olanzapine, Risperidone, Sulpiride, or Tiapride.
  • Treatment with the antidepressants Fluoxetine or Paroxetine within 6 weeks of randomisation.
  • Use of Tetrabenazine within 12 weeks of randomisation, or at any time during the study period.
  • Treatment with any investigational product within 4 weeks of randomisation.
  • Use of tricyclic antidepressants, class I antiarrhythmics, and strong CYP2D6 inhibitors such as Ajmalicine, Chinidin/Quinidine and Ritonavir, within 6 weeks of randomisation.
  • Patients previously included into this study.
  • A prolonged QTc interval at screen (defined as a QTc interval of > 450 msec for males or > 470 msec for females), or other clinically significant heart conditions.
  • Creatinine clearance <40mL/min as measured at the screening visit.
  • Any clinically significant, abnormal, baseline laboratory result which in the opinion of the Investigator, affects the patients' suitability for the study or puts the patient at risk if he/she enters the study.
  • Clinically significant hepatic or renal impairment.
  • Patients with a history of epilepsy or a history of seizure(s) of unknown cause.
  • Severe intercurrent illness, which, in the opinion of the Investigator, may put the patient at risk when participating in the trial or may influence the results of the trial or affect the patients' ability to take part in the trial.
  • Alcohol and/or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
  • Patients with suicidal ideation, defined as a positive score on criteria for major depressive episode, item A9 on the DSM-IV-TR criteria for a Major Depressive Episode.
  • Females who are pregnant or lactating.
  • Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included.
  • Known allergy to any ingredients of the trial medication or placebo.
  • Any previous participation in a clinical study with ACR16.
  • Patients currently receiving deep brain stimulation.
  • Patients with a history of surgical procedures aiming to improve the symptoms of Huntington's disease, such as neural transplantations, lesions of the central nervous system, infusions of neurotrophic agents or previous attempts of deep brain stimulation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00665223


Locations
Show Show 31 study locations
Sponsors and Collaborators
Teva Pharmaceutical Industries
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier: NCT00665223    
Other Study ID Numbers: ACR16 C008
First Posted: April 23, 2008    Key Record Dates
Last Update Posted: July 21, 2016
Last Verified: July 2016
Keywords provided by Teva Pharmaceutical Industries:
Huntington's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dementia
Chorea
Dyskinesias
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders